Use of Intravenous Pulse Steroids to Treat Allergic Bronchopulmonary Aspergillosis in a Non-Compliant Asthmatic Adolescent
Abstract
:1. Introduction
2. Case Presentation
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Shah, A. Allergic bronchopulmonary aspergillosis. Indian J. Chest Dis. Allied Sci. 1998, 40, 41–54. [Google Scholar]
- Agarwal, R.; Noel, V.; Aggarwal, A.N.; Gupta, D.; Chakrabarti, A. Clinical significance of Aspergillus sensitisation in bronchial asthma. Mycoses 2011, 54, e531–e538. [Google Scholar] [CrossRef]
- Agarwal, R. Severe asthma with fungal sensitization. Curr. Allergy Asthma Rep. 2011, 11, 403–413. [Google Scholar] [CrossRef] [PubMed]
- Greenberger, P.A.; Bush, R.K.; Demain, J.G.; Luong, A.; Slavin, R.G.; Knutsen, A.P. Allergic bronchopulmonary aspergillosis. J. Allergy Clin. Immunol. Pract. 2014, 2, 703–708. [Google Scholar] [CrossRef] [Green Version]
- Denning, D.W.; Pashley, C.; Hartl, D.; Wardlaw, A.; Godet, C.; Del Giacco, S.; Delhaes, L.; Sergejeva, S. Fungal allergy in asthma-state of the art and research needs. Clin. Transl. Allergy 2014, 4, 14. [Google Scholar] [CrossRef] [Green Version]
- Greenberger, P.A. Allergic bronchopulmonary aspergillosis. J. Allergy Clin. Immunol. 2002, 110, 685–692. [Google Scholar] [CrossRef] [Green Version]
- Saxena, P.; Choudhary, H.; Muthu, V.; Sehgal, I.S.; Dhooria, S.; Prasad, K.T.; Garg, M.; Saikia, B.; Aggarwal, A.N.; Chakrabarti, A.; et al. Which are the optimal criteria for the diagnosis of allergic bronchopulmonary aspergillosis? A latent class analysis. J. Allergy Clin. Immunol. Pract. 2021, 9, 328–335. [Google Scholar] [CrossRef]
- Sharma, V.K.; Raj, D.; Xess, I.; Lodha, R.; Kabra, S.K. Prevalence and risk factors for allergic bronchopulmonary aspergillosis in Indian children with cystic fibrosis. Indian Pediatr. 2014, 51, 295–297. [Google Scholar] [CrossRef]
- Zander, D.S. Allergic bronchopulmonary aspergillosis: An overview. Arch. Pathol. Lab. Med. 2005, 129, 924–928. [Google Scholar] [CrossRef]
- Nelson, L.A.; Callerame, M.L.; Schwartz, R.H. Aspergillosis and atopy in cystic fibrosis. Am. Rev. Respir. Dis. 1979, 120, 863–873. [Google Scholar]
- Slavin, R.G.; Laird, T.S.; Cherry, J.D. Allergic bronchopulmonary aspergillosis in a child. J. Pediatr. 1970, 76, 416–421. [Google Scholar] [CrossRef]
- Berger, I.; Phillips, W.L.; Shenker, I.R. Pulmonary aspergillosis in childhood. A case report and discussion. Clin. Pediatr. 1972, 11, 178–182. [Google Scholar] [CrossRef] [PubMed]
- Imbeau, S.A.; Cohen, M.; Reed, C.E. Allergic bronchopulmonary aspergillosis in infants. Am. J. Dis Child. 1977, 131, 1127–1130. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.L.; Patterson, R.; Mintzer, R.; Roberts, M.; Rosenberg, M. Allergic bronchopulmonary aspergillosis in pediatric practice. J. Pediatr. 1979, 94, 376–381. [Google Scholar] [CrossRef]
- Chetty, A.; Bhargava, S.; Jain, R.K. Allergic bronchopulmonary aspergillosis in Indian children with bronchial asthma. Ann. Allergy 1985, 54, 46–49. [Google Scholar]
- Singh, M.; Das, S.; Chauhan, A.; Paul, N.; Sodhi, K.S.; Mathew, J.; Chakrabarti, A. The diagnostic criteria for allergic bronchopulmonary aspergillosis in children with poorly controlled asthma need to be re-evaluated. Acta Paediatr. 2015, 104, e206–e209. [Google Scholar] [CrossRef]
- Shah, A.; Kunal, S. A review of 42 asthmatic children with allergic bronchopulmonary aspergillosis. Asia Pacific Allergy 2017, 7, 148–155. [Google Scholar] [CrossRef] [Green Version]
- Patterson, R. Allergic bronchopulmonary aspergillosis and hypersensitivity reactions to fungi. In Fishman’s Pulmonary Diseases and Disorders, 3rd ed.; Fishman, A.P., Elias, J.A., Fishman, J.A., Eds.; McGraw-Hill & Co.: New York, NY, USA, 1998; Volume 1, pp. 777–782. [Google Scholar]
- Agarwal, R.; Chakrabarti, A.; Shah, A.; Gupta, D.; Meis, J.F.; Guleria, R.; Moss, R.; Denning, D.W.; ABPA Complicating Asthma ISHAM Working Group. Allergic bronchopulmonary aspergillosis: Review of literature and proposal of new diagnostic and classification criteria. Clin. Exp. Allergy 2013, 43, 850–873. [Google Scholar] [CrossRef]
- Patterson, R.; Greenberg, P.A.; Radin, R.C.; Roberts, M. Allergic bronchopulmonary aspergillosis: Staging as an aid to management. Ann. Intern. Med. 1982, 96, 286–291. [Google Scholar] [CrossRef]
- Safirstein, B.H.; D’Souza, M.F.; Simon, G.; Tai, E.H.; Pepys, J. Five-year follow up of allergic bronchopulmonary aspergillosis. Am. Rev. Respir. Dis. 1973, 108, 450–459. [Google Scholar]
- Greenberger, P.A.; Patterson, R.; Ghory, A.; Arkins, J.A.; Walsh, T.; Graves, T.; Saker, J. Late sequelae of allergic bronchopulmonary aspergillosis. J. Allergy Clin. Immunol. 1980, 66, 327–335. [Google Scholar] [CrossRef]
- Davis, P.B. Pulmonary disease in cystic fibrosis. In Kendig’s Textbook: Disorders of the Respiratory Tract in Children; Elsevier: Philadelphia, PA, USA, 2000; pp. 884–885. [Google Scholar]
- Rosenstein, B.J.; Eigen, H. Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics 1991, 87, 245–246. [Google Scholar] [CrossRef] [PubMed]
- Cheng, K.; Ashby, D.; Smyth, R. Oral steroids for cystic fibrosis. Cochrane Database Syst. Rev. 2000, 2, CD000407. [Google Scholar]
- Eigen, H.; Rosenstein, B.J. A multicenter study of alternate day prednisone in patients with cystic fibrosis. J. Pediatr. 1995, 126, 515–523. [Google Scholar] [CrossRef]
- Donati, M.A.; Haver, K.; Gerson, W.; Klein, M.; McLaugghlin, F.J.; Wohl, M.E.B. Long term alternate day prednisone therapy in cystic fibrosis. Pediatr. Pulmonol. 1990, 5, A322. [Google Scholar]
- Eyanson, S.; Passo, M.H.; Aldo-Benson, M.A.; Benson, M.D. Methylprednisolone pulse therapy for nonrenal lupus erythematosus. Ann. Rheum Dis. 1980, 39, 377–380. [Google Scholar] [CrossRef]
- Paul, K.; Klettke, U.; Moldenhauer, J.; Müller, K.; Kleinau, I.; Magdorf, K.; Wahn, U. Increasing dose of methylprednisolone pulse therapy treats desquamative interstitial pneumonia in a child. Eur. Respir. J. 1999, 14, 1429–1432. [Google Scholar] [CrossRef] [Green Version]
- Kawasaki, Y.; Suzuki, J.; Suzuki, H. Efficacy of methylprednisolone and urokinase pulse therapy combined with or without cyclophosphamide in severe Henoch-Schoenlein nephritis: A clinical and histopathological study. Nephrol. Dial. Transplant. 2004, 19, 858–864. [Google Scholar] [CrossRef]
- Kauppinen-Mäkelin, R.; Karma, A.; Leinonen, E.; Löyttyniemi, E.; Salonen, O.; Sane, T.; Setälä, K.; Viikari, J.; Heufelder, A.; Välimäki, M. High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroidassociated ophthalmopathy. Acta Ophthalmol. Scand. 2002, 80, 316–321. [Google Scholar] [CrossRef]
- Cohen-Cymberknoh, M.; Blau, H.; Shoseyov, D.; Mei-Zahav, M.; Efrati, O.; Armoni, S.; Kerem, E. Intravenous monthly pulse methylprednisolone treatment for ABPA in patients with cystic fibrosis. J. Cyst. Fibros. 2009, 8, 253–257. [Google Scholar] [CrossRef] [Green Version]
- Thomson, J.M.; Wesley, A.; Byrnes, C.A.; Nixon, G.M. Pulse intravenous methylprednisolone for resistant allergic bronchopulmonary Aspergillosis in cystic fibrosis. Pediatr. Pulmonol. 2006, 41, 164–170. [Google Scholar] [CrossRef] [PubMed]
- Sehgal, I.S.; Agarwal, R. Pulse methylprednisolone in allergic bronchopulmonary aspergillosis exacerbations. Eur. Respir. Rev. 2014, 23, 149–152. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hari, P.; Srivastava, R.N. Pulse Corticosteroid therapy with methylprednisolone or dexamethasone. Indian J. Pediatr. 1998, 65, 557–560. [Google Scholar] [CrossRef] [PubMed]
- Akikusa, J.D.; Feldman, B.M.; Gross, G.J.; Silverman, E.D.; Schneider, R. Sinus bradycardia after intravenous pulse methylprednisolone. Pediatrics 2007, 119, 778–782. [Google Scholar] [CrossRef] [PubMed]
- Lyons, P.R.; Newman, P.K.; Saunders, M. Methylprednisolone therapy in multiple sclerosis: A profile of adverse effects. J. Neurol. Neurosurg. Psychiatry 1988, 51, 285–287. [Google Scholar] [CrossRef] [Green Version]
- Van der Ent, C.K.; Hoekstra, H.; Rijkers, G.T. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 2007, 62, 276–277. [Google Scholar] [CrossRef] [Green Version]
- Zirbes, J.M.; Milla, C.E. Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatr. Pulmonol. 2008, 43, 607–610. [Google Scholar] [CrossRef]
- Kanu, A.; Patel, K. Treatment of allergic bronchopulmonary Aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab). Pediatr. Pulmonol. 2008, 43, 1249–1251. [Google Scholar] [CrossRef]
Time of Assessment | Initial Presentation | after 1st Dose of IV-PS | after 2nd Dose of IV-PS | after 3rd Dose of IV-PS | After 4th Dose of IV-PS | at Follow-Up (1–3 Months) | at 1-Year Follow-Up | |
---|---|---|---|---|---|---|---|---|
Clinical symptoms | Cough | Present | Improving | Improving | Resolved | Resolved | Resolved | Resolved |
Chest pain | Present | Improving | Resolved | Resolved | Resolved | Resolved | Resolved | |
Appetite | Poor | Poor | Better | Better | Better | Excellent | Excellent | |
BMI (kg/m2) | 16.50 | 16.50 | 18.06 | 19.60 | 19.10 | 21.10 | 18.1 | |
Weight (Z-score) | −1.7 | −1.71 | −1.09 | −0.76 | −0.63 | −0.36 | −1.25 | |
Height (Z-score) | −1.39 | −1.39 | −1.51 | −1.60 | −1.32 | −1.47 | −1.51 | |
Pulmonary function tests | FEV1%Pred | 82% | 92% | 97% | 97% | 94% | ||
FVC%Pred | 84% | 97% | 96% | 98% | 95% | |||
FEV1/FVC | 86 | 86 | 89 | 86 | 87 | |||
FEF25-75%Pred | 81% | 91% | 94% | 95% | 94% | |||
Raw%Pred | 202% | 166% | 149% | 192% | 149% | |||
RV%Pred | 113% | 95% | 86% | 96% | 86% | |||
TLC%Pred | 91% | 92% | 92% | 92% | 92% | |||
RV/TLC%Pred | 116% | 97% | 88% | 98% | 88% | |||
LCI 2.5%Pred | 145% | |||||||
FeNO (ppb) | 138.7 | 28.5 | ||||||
Serology | WBC (×109/L) | 17.4 | 18.1 | 11.6 | 23.6 | 10.9 | 10.5 | 11.6 |
Eosinophil (×109/L) | 4.8 | 0.9 | 1.7 | 0 | 1.7 | 2.3 | 1.7 | |
Total IgE (kU/L) | >5000 | >5000 | >5000 | 3816 | 1733 | 1737 | 1900 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hamad, S.G.; Abu-Hasan, M.; AbdulWahab, A. Use of Intravenous Pulse Steroids to Treat Allergic Bronchopulmonary Aspergillosis in a Non-Compliant Asthmatic Adolescent. Children 2022, 9, 252. https://doi.org/10.3390/children9020252
Hamad SG, Abu-Hasan M, AbdulWahab A. Use of Intravenous Pulse Steroids to Treat Allergic Bronchopulmonary Aspergillosis in a Non-Compliant Asthmatic Adolescent. Children. 2022; 9(2):252. https://doi.org/10.3390/children9020252
Chicago/Turabian StyleHamad, Sara G., Mutasim Abu-Hasan, and Atqah AbdulWahab. 2022. "Use of Intravenous Pulse Steroids to Treat Allergic Bronchopulmonary Aspergillosis in a Non-Compliant Asthmatic Adolescent" Children 9, no. 2: 252. https://doi.org/10.3390/children9020252